These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Circulating long non-coding RNA AFAP1-AS1 is a potential diagnostic biomarker for non-small cell lung cancer.
    Author: Li W, Li N, Kang X, Shi K.
    Journal: Clin Chim Acta; 2017 Dec; 475():152-156. PubMed ID: 29080690.
    Abstract:
    BACKGROUND: Recent studies have indicated that long non-coding RNA actin filament-associated protein 1 antisense RNA 1 (lncRNA AFAP1-AS1) was increased in non-small cell lung cancer and associated with unfavorable patient prognosis. AFAP1-AS1 also participates in promoting invasion and metastasis in non-small cell lung cancer cells. However, the diagnosis value of serum AFAP1-AS1 in non-small cell lung cancer was unclear. In this study, we aimed to explore whether circulating AFAP1-AS1 can be used as a diagnostic biomarker for non-small cell lung cancer. METHOD: The serum AFAP1-AS1 expression level in 126 non-small cell lung cancer patients and 60 healthy controls was detected by quantitative real-time polymerase chain reaction (qRT-PCR). The concentrations of serum cyfra21-1 were detected through chemiluminescence method using the Roche Cobas e601. Receiver operating characteristic curve analysis was applied to assess the diagnostic value of serum AFAP1-AS1 and cyfra21-1 in non-small cell lung cancer. RESULT: The results demonstrated that AFAP1-AS1 expression level was significantly elevated in non-small cell lung cancer patients compared with that in normal controls (p=0.000). Serum AFAP1-AS1 could be used as molecular marker for distinguishing non-small cell lung cancer patients from healthy people with an area under the curve of 0.759 (95% confidence interval=0.692-0.826; p=0.000). The combination of FAP1-AS1 and cyfra21-1 showed that the area under the curve was 0.860 (95% confidence interval=0.808-0.912; p=0.000). Further analysis found that high serum AFAP1-AS1 expression levels correlated with distant metastasis (p=0.03), lymph node metastasis (p=0.017), poor clinical stage (p=0.019), and larger tumor size (p=0.015). Furthermore, AFAP1-AS1 was significantly upregulated in positive distant metastasis group (p=0.003), positive lymph node metastasis (p=0.017), poor clinical stage group (p=0.019), and larger tumor size group (p=0.015). CONCLUSION: Serum AFAP1-AS1 could serve as an ideal combined biomarker for the diagnosis of non-small cell lung cancer.
    [Abstract] [Full Text] [Related] [New Search]